ArticleHepatology international2014
Vitamin D modulates biliary fibrosis in ABCB4-deficient mice.
Article in Hepatology international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Trial
- Vitamin D receptor suppresses pulmonary fibroblast activation by downregulating the TGF-β1/Smad signaling pathway.Histochemistry and cell biology · 2026Article
- The gut microbiota in liver transplantation recipients during the perioperative and postoperative recovery period.Frontiers in microbiology · 2025Article
- Review
- Vitamin D alleviates hypothyroidism associated liver dysfunction: Histological and biochemical evidence.Heliyon · 2023Article
- Bile Acids-A Peek Into Their History and Signaling.Endocrinology · 2022Article
- The Role of Vitamin D and Vitamin D Binding Protein in Chronic Liver Diseases.International journal of molecular sciences · 2022Review
- Serum 25-hydroxyvitamin D and C-reactive protein and plasma von Willebrand concentrations in 23 dogs with chronic hepatopathies.Journal of veterinary internal medicine · 2022Article
- Vitamin D in liver cancer: novel insights and future perspectives.Croatian medical journal · 2022Review
- Effects of blocking chemokine receptor CCR1 with BX471 in two models of fibrosis prevention and rescue in mice.Biochemistry and biophysics reports · 2021Article
- Serum vitamin D status in sick cats with and without cholestatic liver disease.Journal of feline medicine and surgery · 2020Article
- Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice.American journal of physiology. Gastrointestinal and liver physiology · 2020Article
- Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases.Nutrients · 2020Review
- Primary biliary cholangitis: pathogenesis and therapeutic opportunities.Nature reviews. Gastroenterology & hepatology · 2020Review
- Antifibrotic Effects of 1,25(OH)Digestive diseases and sciences · 2019Article
- Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis.Digestive diseases and sciences · 2019Review
- Associations between Vitamin D and Liver Function and Liver Fibrosis in Patients with Biliary Atresia.Gastroenterology research and practice · 2019Article
- ApaI polymorphism of vitamin D receptor affects health-related quality of life in patients with primary sclerosing cholangitis.PloS one · 2017Article
- Targeting Hepatic Fibrosis in Autoimmune Hepatitis.Digestive diseases and sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImpaired vitamin D receptor signaling represents an aggravating factor during liver injury, and recent studies suggest that vitamin D might exert a protective role in chronic hepatobiliary diseases. We hypothesized that vitamin D supplementation would ameliorate liver fibrosis in ATP-binding cassette transporter B4 knockout (Abcb4 (-/-)) mice as a preclinical model of sclerosing cholangitis.
methodsAbcb4 (-/-) and wild-type mice were fed a regular chow diet (600 IU vitamin D/kg food) or diets with lower (100 IU/kg) and higher (2,400 IU/kg) vitamin D concentrations for 12 weeks. Serum 25-hydroxyvitamin D concentrations were measured by chemiluminescence immunoassays. Liver injury and biliary fibrosis were assessed by liver enzyme activities, histopathology and hepatic collagen contents. Hepatic mRNA expression of markers for fibrosis, vitamin D and bile acid metabolism were analyzed by quantitative PCR.
resultsDifferent vitamin D concentrations were observed depending on genotype and diet group, with Abcb4 (-/-) mice on the control diet showing lower vitamin D concentrations compared to wild-type mice. Abcb4 (-/-) animals on the low vitamin D diet demonstrated the most advanced liver fibrosis and highest hepatic collagen contents. Feeding Abcb4 (-/-) mice a high vitamin D diet enriched serum vitamin D levels, lowered liver enzyme activities, altered expression levels of profibrogenic genes and ameliorated, in part, liver injury.
conclusionsThis is the first report to demonstrate that fibrogenesis in the established Abcb4 (-/-) model is influenced by vitamin D supplementation. Since vitamin D modulates sclerosing cholangitis in vivo, we speculate that sufficient vitamin D intake might improve liver damage and induce antifibrotic effects in chronic cholestasis in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.